الفهرس 
PREECLAMPSIAOnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
Background: Cancer Antigen-125 (CA-125) is a glycoprotein antigen, which is generally expressed in epithelial ovarian cancer and non-malignant pelvic diseases like endometriosis, fibroids, pregnancy, and pelvic inflammatory disease. Aim of the Work: to assess the association between Adipokines, Insulin resistance and Obesity in women with PCOS, and its clinical significance. This case-control study study will be conducted in Ain Shams University Maternity Hospital, starting from January, 2017 till the end of the study population on 100 PG women of at least 30wks. Results: When the cut-off point for serum CA-125 concentrations was accepted as 66 IU/ml, the sensitivity, specificity, positive and negative predictive values of this unique biochemical marker were, 90.0%, 92.19%, 78.3% and 96.7% respectively for the detection of preeclamptic pregnancies. Conclusion: CA 125 is a promising biomarker for the screening of preeclampsia. Recommendations: Further studies are needed to confirm the results obtained by this study.